Pharmaceuticals—regulatory framework

Introduction to the regulation of medicinal products

A medicinal product is defined as a substance that is either:

  1. presented as preventing or treating disease, or

  2. used to correct or modify a physiological function by pharmacological, immunological or metabolic action, or to make a medical diagnosis

It is often obvious whether a product should be classified as a medicinal product, medical device, cosmetic product, food, or a biocide. On the other hand, the regulatory status of so-called ‘borderline products’ is not immediately clear. The regulatory classification of a product can have important ramifications, for example, on how the product is regulated (and by whom), how long it will take before such product can be commercialised (especially if pre-market approval is required), how the product can be marketed and what advertising claims can be made etc. For an analysis of the definition of medicinal product and the borderline between medicinal products and other products, see Practice Note: Introduction to borderline products.

The borderline between cosmetic products and those that are regulated as a medicinal product or medical device or have health claims

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest Life Sciences News

Life Sciences weekly highlights—26 February 2026

This week's edition of Life Sciences weekly highlights includes a Law 360 analysis on the Court of Appeal dismissing Salts Healthcare Ltd’s renewed attempts to find Pelican Healthcare Ltd liable for infringing one of its patents over an ostomy bag and an analysis by Hepworth Browne of the UK Supreme Court’s ruling in Emotional Perception AI Ltd v Comptroller-General of Patents, in which the court reshaped the foundations of UK patent law by reorientating the assessment of exclusions to patentability. Also included, is news that the Court of Appeal dismissed the appeals in a biotechnology patent dispute regarding the production of microbial oil for nutritional products, the EU General Court issued orders in challenges concerning the revised Urban Wastewater Treatment Directive (UWWTD) on the grounds of admissibility, not addressing the substantive question of the legality of the Extended Producer Responsibility (EPR) scheme, the MHRA and NICE have jointly published guidance on the Integrated Scientific Advice service, EFPIA published a report assessing the economic and societal contribution of industry-sponsored clinical trials in Europe as well as a comparative analysis of biopharmaceutical strategies across ten countries, and news that the UK Research and Innovation announced its first AI strategy, the Department for Science, Innovation and Technology (DSIT) announced £150m for three UK Research and Innovation programmes, as well as MHRA updates reporting a rise in clinical investigations, the launch of a fee waiver pilot for small firms, a statement on the paused PATHWAYS clinical trial, and enforcement action involving the seizure of unlicensed weight loss medicines, among other stories.

View Life Sciences by content type :

Popular documents